Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insight into the allosteric inhibition of Abl kinase.

Journal of chemical information and modeling - 27 May 2014

Fallacara Anna Lucia, Tintori Cristina, Radi Marco, Schenone Silvia, Botta Maurizio

Abstract excerpt

Abl kinase inhibitors targeting the ATP binding pocket are currently used as a front-line therapy for the treatment of chronic myelogenous leukemia (CML), but their use has significant limitation because of the development of drug resistance (especially due to the T315I mutation). Two compounds (GNF-2 and BO1) have been found able to inhibit the Abl activity through a peculiar mechanism of action. Particularly,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Adenosine Triphosphate
Share to Allosteric Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Stability

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Share to Proto-Oncogene Proteins c-abl

Share to src Homology Domains

Source

Identifiers

PMID: 24787133
DOI: 10.1021/ci500060k

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insight into the allosteric inhibition of Abl kinase.PMID 24787133Read ↗

Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.Semantic proximity Read ↗

Expanding the diversity of allosteric bcr-abl inhibitors.Semantic proximity Read ↗

Imatinib can act as an Allosteric Activator of Abl Kinase.Semantic proximity Read ↗

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.Semantic proximity Read ↗

A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.Semantic proximity Read ↗

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.Semantic proximity Read ↗

Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.Semantic proximity Read ↗

Structure, Regulation, Signaling, and Targeting of Abl Kinases in CancerSemantic proximity Read ↗

The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.Semantic proximity Read ↗

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.Semantic proximity Read ↗

Structure and dynamic regulation of Abl kinases.Semantic proximity Read ↗

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.